Brooklyn ImmunoTherapeutics Inc. (BTX): Price and Financial Metrics


Brooklyn ImmunoTherapeutics Inc. (BTX): $4.10

0.00 (0.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BTX Stock Price Chart Interactive Chart >

Price chart for BTX

BTX Price/Volume Stats

Current price $4.10 52-week high $10.10
Prev. close $0.21 52-week low $0.17
Day low $3.62 Volume 127,880
Day high $4.20 Avg. volume 515,543
50-day MA $0.36 Dividend yield N/A
200-day MA $1.28 Market Cap 241.30M

Brooklyn ImmunoTherapeutics Inc. (BTX) Company Bio


Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.


BTX Latest News Stream


Event/Time News Detail
Loading, please wait...

BTX Latest Social Stream


Loading social stream, please wait...

View Full BTX Social Stream

Latest BTX News From Around the Web

Below are the latest news stories about BROOKLYN IMMUNOTHERAPEUTICS INC that investors may wish to consider to help them evaluate BTX as an investment opportunity.

Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress

SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced that Matt Angel, Ph.D., Interim Chief Executive Officer of Eterna, will present at the iPSC-Derived Immunotherapies Congress, taking place October 18-19, 2022 in Boston. Details of Presentation Title: Avoiding Vector Integration Using mRNA Vectorization of

Yahoo | October 18, 2022

Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics

The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Exacis’ iNK and iT cells, made using non-viral, episome-free cell engineering technology, include advanced ‘stealthing’ edits, and can target virtually any cancer antigen SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop

Yahoo | October 17, 2022

Brooklyn ImmunoTherapeutic changing name to Eterna Therapeutics on Monday

MARKET PULSE Brooklyn ImmunoTherapeutics Inc. (BTX) said Tuesday it’ll change its stock trading ticker to ERNA on Monday, Oct. 17, as part of a name change to Eterna Therapeutics Inc. The San Diego-based clinical stage biopharmaceutical company said the new name reflects its focus on developing advanced therapies using its patented mRNA cell engineering technologies.

Yahoo | October 11, 2022

Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate Updates

New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company’s shares to trade under new ticker symbol “ERNA” starting on October 17, 2022, and a one-for-twenty share consolidation will become effective on that date SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Na

Yahoo | October 11, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, investor!

William White on InvestorPlace | September 20, 2022

Read More 'BTX' Stories Here

BTX Price Returns

1-mo N/A
3-mo N/A
6-mo -60.50%
1-year -91.46%
3-year -95.44%
5-year -98.24%
YTD N/A
2022 0.00%
2021 -6.92%
2020 1.82%
2019 12.82%
2018 -53.68%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6281 seconds.